EUCOMED Comments on the Commission Working Document – Consultation on the Future

The mission of Eucomed is to improve patient and clinician access to modern, innovative and reliable medical technology. The medical technology sector employs 435,000 people across Europe and it is growing at an annual rate of between 5 % and 6%.


Auteurs : | Ecrit le 14/04/10 | envoyer l'article par mail envoyer par mail | impression Imprimer | Document Joint

Eucomed represents 4.500 designers, manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and amelioration of disease and disability.

The mission of Eucomed is to improve patient and clinician access to modern, innovative and reliable medical technology. The medical technology sector employs 435,000 people across Europe and it is growing at an annual rate of between 5 % and 6%.

Medical technology is one of the most innovative industries in Europe. Up to 8 (or €5.8bn) of medical technology sales are reinvested in R&D. Products have an average life cycle of only 18 months before an improved product is developed.

Eucomed applauds the intention and objectives of the EU 2020 Strategy paper . One of the major challenges though will be to ensure that future– and the review of current – policies and their implementation will be in line with the outlined strategy. A clear example of this is the issue around late payments (review of the EU Directive on Late Payments – see under 2).

Eucomed believes it can be an important partner in the discussion on how to further refine and implement such strategy.

General comments

The paper rightly indicates that cutting public spending in forward looking areas such as research, could jeopardize achieving the EU 2020 objectives. This is also true for spending in health and healthcare. While often considered by governments as a cost, providing sufficient funding for healthcare and striving to make the healthcare system more efficient by early adoption of new technologies, is instead an invaluable investment in society. A healthy society is one that is more likely to have better economic growth. For the EU 2020 Strategy to be successful, the EU and the member states will need to work together to make healthcare provision and the healthcare systems overall more efficient, not only by sharing best practices, but also by evaluating on an ongoing basis how such best practices in one member state can be implemented successfully in another member state.

How can the medical technology sector contribute to the goals of the EU 2020 Strategy ?

How can the medical technology sector contribute to the goals of the EU 2020 Strategy ?

growing at 5% to 6% annually. Safeguarding and further encouraging innovation could maintain and perhaps increase such employment growth rate.

This requires a number of mechanisms to ensure ongoing innovation within the EU, as well as a clear strategy to ensure the European medical technology sector can compete at equal level playing field globally.

…telechargez l’article complet en "document joint"


Ecrit le 14/04/10 | envoyer l'article par mail envoyer par mail | impression Imprimer | Document Joint

Ressources doc : International

Health related quality-of-life scales specific for chronic venous disorders of the lower limbs

>Lire cette présentation en pleine page

Lire la suite >

The Governance of Regulators - OECD best Practice Principles for Regulatory Policy

Retrouvez l'intégralité du document a télécharger

Lire la suite >

OECD Factbook 2014 - ECONOMIC, ENVIRONMENTAL AND SOCIAL STATISTICS

Retrouvez l'intégralité du document a télécharger

Lire la suite >

HEALTHY SAVINGS - Medical Technology and the Economic Burden of Disease

Retrouvez l'intégralité du document a télécharger

Lire la suite >

European Alliance for Personalised Medicine INNOVATION and PATIENT ACCESS to PERSONALISED MEDICINE

Retrouvez l'intégralité du document a télécharger

Lire la suite >

Atelier JGEM-SFES méthodes pratiques de modélisation

Retrouvez ci-dessous les présentations des intervenants : 1- (...)

Lire la suite >

Interview de Guy Vallancien pour la publication de son livre « La Médecine (...)

La SFES interviewe Guy Vallancien à l’occasion de la publication de (...)

Lire la suite >

L’analyse du risque de change Par Béatrice Majnoni d’Intignano, Professeur (...)

1 - Votre article dans le Monde daté samedi 18 avril a fait (...)

Lire la suite >

Séminaire SFES JGEM 2015

Retrouvez ci-dessous les présentations des intervenants : 1- (...)

Lire la suite >

Évenements de l’année en économie médicale 2015 - 22 Janvier 2015

Lire la suite >

Interview de Christian BABUSIAUX et Richard DECOTTIGNIES Président et (...)

Paul GARASSUS Merci de recevoir la SFES. Nous vous rencontrons (...)

Lire la suite >

Séminaire JGEM SFES CES - Paris, 23 Janvier 2014

Retrouvez ci-dessous les présentations des intervenants : Un (...)

Lire la suite >

Médicaments : Accès au marché et contrats de performance - Paris, 11 décembre (...)

Comment maintenir l’accès à l’innovation thérapeutique, compte tenu (...)

Lire la suite >

Health outcomes in Europe : The QALY controversy - Bruxelles, 25 Janvier (...)

Lire la suite >

Contrainte financière, Evolution des méthodes de paiement, Transformation des (...)

Salle des Actes - 14h00- 17h00 - Faculté des sciences (...)

Lire la suite >

Séminaire - Actualités politiques et managériales en santé

Ce séminaire concrétise le partenariat de cinq universités autour (...)

Lire la suite >

Le retour sur investissement des dépenses engagées dans la lutte contre le (...)

Résumé Les autorités réglementaires européennes qui délivrent les (...)

Lire la suite >

Jean-Luc Harousseau

Paul GARASSUS, SFES (PG) – Quel positionnement prioritaire de la (...)

Lire la suite >

Quel modèle économique hospitalier ? Ce que l’Europe peut nous (...)

Lire la suite >

Médicaments : Accès au marché, arbitrage des valeurs, fixation des (...)

7ème séminaire Descartes – Berkeley – Evry Jeudi 24 mai 2012, Salle (...)

Lire la suite >